Pediatric Asthma Treatment Market: Global Size, Share, Trends, Growth and Forecast 2022-2032

Pediatric Asthma Treatment Market: Overview and Definition

The global pediatric asthma treatment market is expected to reach USD 48.5 billion by 2032, at a CAGR of 8.5% during the forecast period 2022-2032. 

Pediatric asthma is a chronic respiratory disease that affects children and adolescents. It is characterized by inflammation and constriction of the airways, leading to breathing difficulties, coughing, and wheezing. The treatment of pediatric asthma aims to control symptoms and prevent exacerbations. The treatment typically includes a combination of medications and non-pharmacological interventions.

Medications: The mainstay of pediatric asthma treatment is the use of medications to reduce inflammation, relieve symptoms, and prevent exacerbations. The most commonly used medications for pediatric asthma include:

• Inhaled corticosteroids (ICS): These medications reduce inflammation in the airways and are typically used as the first-line treatment for persistent asthma.
• Short-acting beta-agonists (SABAs): These medications provide rapid relief of asthma symptoms by relaxing the airway smooth muscles and opening the airways.
• Long-acting beta-agonists (LABAs): These medications provide long-term control of asthma symptoms and are typically used in combination with ICS in moderate to severe asthma.
• Leukotriene modifiers: These medications reduce inflammation by blocking the action of leukotrienes, which are chemicals that contribute to inflammation in the airways.
• Immunomodulators: These medications are used in severe asthma to reduce inflammation and suppress the immune response.

Non-pharmacological interventions: In addition to medications, non-pharmacological interventions can help manage pediatric asthma. These include:

• Allergen avoidance: Identifying and avoiding triggers that can exacerbate asthma symptoms, such as dust mites, pollen, and animal dander.
• Education and self-management: Teaching children and their caregivers about asthma, its triggers and warning signs, proper use of medications, and how to manage asthma exacerbations.
• Physical activity: Encouraging children with asthma to engage in physical activity to improve lung function and overall health.
• Asthma action plan: Developing an asthma action plan with the child's healthcare provider to manage asthma symptoms and prevent exacerbations.

Pediatric Asthma Treatment Market: Key Drivers

The pediatric asthma treatment market is driven by several factors, including:

Increasing prevalence of pediatric asthma: The prevalence of pediatric asthma has been increasing in recent years, and it is now one of the most common chronic diseases affecting children. This trend is driving the demand for effective treatments and contributing to the growth of the pediatric asthma treatment market.

Advances in treatment options: There have been significant advances in the treatment options available for pediatric asthma, including new medications, delivery devices, and non-pharmacological interventions. These advances are driving innovation in the market and providing better treatment options for children with asthma.

Focus on personalized medicine: The increasing focus on personalized medicine is driving the development of new treatments that are tailored to individual patients based on their genetic and physiological characteristics. This trend is expected to continue to drive growth in the pediatric asthma treatment market in the coming years.

Increasing awareness and education: There is growing awareness and education about pediatric asthma among healthcare providers, patients, and their families. This trend is driving earlier diagnosis and treatment of asthma and improving overall outcomes for children with the disease.

Government initiatives: Many governments around the world are implementing initiatives to improve the management of pediatric asthma. For example, some countries have established national asthma control programs or guidelines that aim to improve the diagnosis, treatment, and management of asthma in children. These initiatives are expected to drive growth in the pediatric asthma treatment market.

Pediatric Asthma Treatment Market: Challenges

The pediatric asthma treatment market faces several challenges, including:

High cost of treatment: The cost of treatment for pediatric asthma can be high, particularly for patients with severe or uncontrolled asthma. This can be a barrier to access for some patients, especially those from low-income families or without adequate health insurance.

Adherence to treatment: Adherence to treatment can be challenging for pediatric asthma patients, particularly for those who require long-term daily medication. Poor adherence can lead to poor control of symptoms, increased risk of exacerbations, and decreased quality of life for patients.

Safety concerns: Some asthma medications, particularly those used for long-term control, can have side effects or safety concerns. For example, long-term use of inhaled corticosteroids has been associated with decreased bone density, growth suppression, and other potential risks.

Limited treatment options: While there have been significant advances in the treatment of pediatric asthma, there are still some patient populations for which treatment options are limited. For example, some patients with severe or refractory asthma may not respond to currently available treatments and may require new therapies to be developed.

Disparities in healthcare access: There are disparities in healthcare access and asthma outcomes among different racial and ethnic groups, as well as between urban and rural areas. Addressing these disparities is a challenge that requires efforts to improve access to care, education, and treatment for all pediatric asthma patients.

Pediatric Asthma Treatment Market: Segmentation

The pediatric asthma treatment market can be segmented based on several factors, including:

Treatment type: The market can be segmented into medication-based treatments and non-medication-based treatments. Medication-based treatments include inhaled corticosteroids, bronchodilators, leukotriene modifiers, and other medications. Non-medication-based treatments include allergen avoidance, education, and lifestyle modifications.

Route of administration: Medication-based treatments can be further segmented based on the route of administration, including inhaled medications, oral medications, and intravenous medications.

Age group: The market can be segmented by age group, including infants, toddlers, preschoolers, school-age children, and adolescents.

Distribution channel: The market can also be segmented based on the distribution channel, including hospital pharmacies, retail pharmacies, and online pharmacies.

Geography: The market can be segmented by geography, including North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.

Pediatric Asthma Treatment Market: Regional Synopsis

The pediatric asthma treatment market is a global market, with significant variations in prevalence, treatment patterns, and healthcare systems across different regions. Here is a brief regional synopsis of the market:

North America: North America is the largest market for pediatric asthma treatment, with the US being the largest contributor. The high prevalence of pediatric asthma, well-established healthcare infrastructure, and high awareness about asthma management contribute to the market growth in this region.

Europe: Europe is the second-largest market for pediatric asthma treatment. The increasing prevalence of asthma, particularly in urban areas, and the availability of advanced treatments contribute to the market growth in this region.

Asia-Pacific: The Asia-Pacific region is expected to be the fastest-growing market for pediatric asthma treatment. The rising prevalence of asthma, particularly in developing countries, along with increasing healthcare spending and improving healthcare infrastructure, is driving the market growth in this region.

Latin America: The market for pediatric asthma treatment in Latin America is growing, driven by increasing awareness and education about asthma management, the availability of new treatments, and increasing healthcare investment.

Middle East and Africa: The pediatric asthma treatment market in the Middle East and Africa is relatively small, but it is expected to grow in the coming years due to increasing healthcare investment, improving healthcare infrastructure, and the rising prevalence of asthma in some countries in the region.

Pediatric Asthma Treatment Market: Key Players

• AstraZeneca
• Teva Pharmaceutical Industries Ltd.
• Merck & Co., Inc.
• Boehringer Ingelheim International GmbH
• Sanofi
• Novartis International AG
• Vectura Group plc
• Mylan N.V.
• Chiesi Farmaceutici S.p.A.
• GlaxoSmithKline

Pediatric Asthma Treatment Market: Recent Developments

Here are some recent developments in the pediatric asthma treatment market:

In January 2021, AstraZeneca received FDA approval for its new self-administered asthma treatment Fasenra (benralizumab) auto-injector for patients aged 12 years and older. Fasenra is an interleukin-5 receptor antagonist indicated for the maintenance treatment of severe eosinophilic asthma.

In December 2020, GlaxoSmithKline and Sanofi announced that they had signed a collaboration agreement with the US government to develop and supply up to 100 million doses of their COVID-19 vaccine candidate. The vaccine uses GSK's adjuvant technology and Sanofi's recombinant protein antigen technology.

In November 2020, Novartis announced that the US FDA had approved its Enerzair Breezhaler (indacaterol acetate, glycopyrrolate, and mometasone furoate) for the maintenance treatment of asthma in patients aged 12 years and older. The Enerzair Breezhaler is the first and only asthma treatment to combine three medicines in a single inhaler.

In October 2020, Boehringer Ingelheim announced that its new asthma treatment Spiriva Respimat (tiotropium bromide) had been approved by the European Commission for the maintenance treatment of asthma in patients aged 6 years and older. Spiriva Respimat is a long-acting muscarinic antagonist.

In September 2020, Teva Pharmaceutical Industries Ltd. announced the launch of its generic version of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) in the US. Advair Diskus is a combination treatment for asthma and chronic obstructive pulmonary disease.